Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Finance Watch: Pfizer Ventures' Dalton Makes Sense Of Neuroscience Focus Within New $600m VC Fund Commitment

Executive Summary

Venture Capital Edition: Pfizer deprioritized neuroscience as an early R&D focus earlier this year, but will stay involved by spending 25% of the $600m added to its venture fund on neurology investments. Also, China VC investment keeps up fast pace and Alta Partners closes a new $130m health care fund.

Advertisement

Related Content

Deal Watch: Avid Transitions Into CDMO By Offloading Cancer Program To Oncologie
Finance Watch: Happy Holidays For Flagship With A New $618m Fund
Deal Watch: Celgene The Latest To Buy Into Nimbus’ Computational Chemistry Approach
Finance Watch: Roivant Raises $1.1bn, Relying On Private Equity To Fund New Companies
Sirnaomics Bets On RNAi In China With First IND Approval
HitGen Hits China Drug Discovery Jackpot With MNC Tie-ups
Finance Watch: Raising Cash Before A Trump Slump, La Jolla Nabs $125m, Akcea Eyes $100m IPO
Biotech VC Funding Rises As Fewer Companies Get More Dollars
Early February VC Tally: 6 Biotech Firms Raise $153.5m

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC123240

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel